Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19,

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the Company’s experimental drug, in …, Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the Company’s experimental drug, in …, Read More

Scroll to Top